CoChat

The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology

Open access
Kirchhof, Paulus, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Sipido, Karin R., ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Cowie, Martin R., ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Eschenhagen, Thomas, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Fox, Keith A.A., ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Katus, Hugo, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Schroeder, Stefan, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Schunkert, Heribert, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Priori, Silvia, ESC CRT R&D and European Affairs Work Shop on Personalized Medicine, Alonso, Angeles, Chezaubernard, Claire, Doevendans, Pieter, Eschenhagen, Thomas, Fox, Keith, Katus, Hugo, Khder, Yasser, Kirchhof, Paulus, Kramer, Frank, Kristensen, Steen, Maitland-Van der Zee, Anke-Hilse, Oertelt-Prigione, Sabine, Pinto, Fausto, Pocock, Stuart, Priori, Silvia G., Sartorius, Alfonso, Schott, Daniela, Schroeder, Stefan, Schunkert, Heribert, Schwab, Matthias, Sipido, Karin, Svensson, Anders, Swedberg, Karl, Wallentin, Lars, Weimers, Marianne, Herttuala, Seppo Yla · 2014 · European Heart Journal
Cited by 90

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Personalized medicine implies a tailored approach to patients that offers more effective therapy for each individual, reduces risks and avoids unnecessary treatments or diagnostic interventions. Treatment of patients with cardiovascular diseases (CVDs) has markedly improved through the evaluation of new therapy concepts in large, controlled trials that provide evidence-based guidance. While this approach has, e.g. reduced morbidity and mortality in acute coronary artery disease and extended significantly life expectancy in chronic ischaemic heart disease and heart failure, there remains a high, and increasing, burden of CVD. Conditions such as atrial fibrillation, acute heart failure, or sudden cardiac death still cause unacceptable morbidity and mortality in the population. Furthermore, patients who survive acute cardiac events often require long-term treatment for chronic conditions. The development and implementation of a more personalized management offer potential to significantly improve outcome. Controlled trials by nature apply the same approach and therapy to patients with the same disease entity, even if with different disease stages and manifestations. Yet clinical cardiological practice aims to take into account differences between individual patients into therapeutic decisions. Initial concepts of personalized medicine focused heavily on genetic markers, particularly in oncology, but equally in CVD where genomics was the first marker which was considered.1,2 This has yielded interesting insights for some areas, such as unwanted drug effects,3 but this one-sided approach has limitations and a more comprehensive strategy is needed.4 Application of risk stratification based on clinical, biochemical, imaging, and/or genomic markers is already used to tailor therapy, but remains fragmented and research often focuses on single aspects of personalization. Based on a workshop held by the European Society of Cardiology, this report summarizes the current state of stratified cardiovascular care and examines the available and required tools to progress towards more personalized cardiovascular medicine. Actions are proposed that are necessary to expand and implement personalized medicine in CVDs and overcome potential hurdles. In recent years CVD has been leading the medical field in moving away from treatment defined by individual physicians to treatment based on evidence and guidelines. Large randomized clinical trials (RCTs) and population studies have identified the benefit of novel therapies such as β-blockers, ACE-inhibitors, anticoagulants, PCI and stents,5–8 defibrillators, and pacemakers.9 The evidence-based approach has led to major reductions in mortality in acute coronary syndromes and stroke10,11 in a time when progress in other areas has been much slower.12 Recently, however, some limitations to the evidence-based medicine have emerged. For example, it has been recognized that this approach is driven by the enrolment criteria of the trials and may not provide results that are applicable to other subgroups of patients such as those excluded by the trial. For this reason, the need for different approaches to investigate efficacy of therapies in selected populations has promoted the concept of ‘personalized medicine’ defined as the selection of diagnostic and therapeutic strategies based on prospectively validated patient characteristics, integrating clinical parameters, biochemical, usually blood-based biomarkers, and genetic information. The adoption of this broad definition of ‘personalized medicine’ is rooted in the recognition that contemporary cardiovascular care is already using components of individualized medicine. Assessment of an individual based on an assembly of risk factors, which is converted into risk scores (e.g. SCORE, GRACE,13 TIMI,14 CHA2DS2VASc,15 MAGGIC16), is an important, first step towards individualization in current cardiology practice which requires better implementation.17,18 The electrocardiogram is an important and immediately available ‘point-of-care’ diagnostic tool that provides further invaluable information, e.g. in the detection of ST elevation myocardial infarction in patients with chest pain, arrhythmias such as atrial fibrillation or ventricular tachycardias, but also information on heart rate, QRS widening, PR, or QT interval. Further individualization of care is based on biochemical markers such as elevated serum troponins which guide an invasive treatment strategy in patients with acute chest pain when clinical information is integrated.19 On a similar line, BNP measurements can help differentiate heart failure from non-cardiac causes of breathlessness,20 and troponin or d-dimer may be useful to further estimate risk in patients with atrial fibrillation.21 Further individualization of therapy comes through imaging. Echocardiography has become a first line tool where, e.g. reduced left ventricular function guides therapy with, e.g. ACE-inhibitors and β-b

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehu312

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 90

Metadata

Authors
Kirchhof, P., Medicine, E. C. R. A. E. A. W. S. O. P., Sipido, K. R., Medicine, E. C. R. A. E. A. W. S. O. P., Cowie, M. R., Medicine, E. C. R. A. E. A. W. S. O. P., Eschenhagen, T., Medicine, E. C. R. A. E. A. W. S. O. P., Fox, K. A. A., Medicine, E. C. R. A. E. A. W. S. O. P., Katus, H., Medicine, E. C. R. A. E. A. W. S. O. P., Schroeder, S., Medicine, E. C. R. A. E. A. W. S. O. P., Schunkert, H., Medicine, E. C. R. A. E. A. W. S. O. P., Priori, S., Medicine, E. C. R. A. E. A. W. S. O. P., Alonso, A., Chezaubernard, C., Doevendans, P., Eschenhagen, T., Fox, K., Katus, H., Khder, Y., Kirchhof, P., Kramer, F., Kristensen, S., Maitland-Van der Zee, A.-H., Oertelt-Prigione, S., Pinto, F., Pocock, S., Priori, S. G., Sartorius, A., Schott, D., Schroeder, S., Schunkert, H., Schwab, M., Sipido, K., Svensson, A., Swedberg, K., Wallentin, L., Weimers, M., & Herttuala, S. Y.
Venue
European Heart Journal
Published
2014-08-22
Volume
35
Issue
46
Pages
3250-3257
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2153131788
Cited by
90
References
25
FWCI
11.65
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. https://app.cochat.ai/papers/10.1093/eurheartj/ehu312
The paper
Kirchhof, P., Medicine, E. C. R. A. E. A. W. S. O. P., Sipido, K. R., Medicine, E. C. R. A. E. A. W. S. O. P., Cowie, M. R., Medicine, E. C. R. A. E. A. W. S. O. P., Eschenhagen, T., Medicine, E. C. R. A. E. A. W. S. O. P., Fox, K. A. A., Medicine, E. C. R. A. E. A. W. S. O. P., Katus, H., Medicine, E. C. R. A. E. A. W. S. O. P., Schroeder, S., Medicine, E. C. R. A. E. A. W. S. O. P., Schunkert, H., Medicine, E. C. R. A. E. A. W. S. O. P., Priori, S., Medicine, E. C. R. A. E. A. W. S. O. P., Alonso, A., . . . Herttuala, S. Y. (2014). The continuum of personalized cardiovascular medicine: a position paper of the European Society of Cardiology. European Heart Journal. https://doi.org/10.1093/eurheartj/ehu312

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.